JP2024527109A - Ｋｒａｓ変異体がんの処置のための方法および組成物 - Google Patents

Ｋｒａｓ変異体がんの処置のための方法および組成物 Download PDF

Info

Publication number
JP2024527109A
JP2024527109A JP2024505416A JP2024505416A JP2024527109A JP 2024527109 A JP2024527109 A JP 2024527109A JP 2024505416 A JP2024505416 A JP 2024505416A JP 2024505416 A JP2024505416 A JP 2024505416A JP 2024527109 A JP2024527109 A JP 2024527109A
Authority
JP
Japan
Prior art keywords
kras
inhibitor
poziotinib
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527109A5 (https=
Inventor
ジョン ブイ． ヘイマッチ
ジャクリーン ピー． ロビショー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2024527109A publication Critical patent/JP2024527109A/ja
Publication of JP2024527109A5 publication Critical patent/JP2024527109A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024505416A 2021-07-29 2022-07-29 Ｋｒａｓ変異体がんの処置のための方法および組成物 Pending JP2024527109A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227237P 2021-07-29 2021-07-29
US63/227,237 2021-07-29
PCT/US2022/074317 WO2023010121A1 (en) 2021-07-29 2022-07-29 Methods and compositions for treatment of kras mutant cancer

Publications (2)

Publication Number Publication Date
JP2024527109A true JP2024527109A (ja) 2024-07-19
JP2024527109A5 JP2024527109A5 (https=) 2025-08-05

Family

ID=85087345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505416A Pending JP2024527109A (ja) 2021-07-29 2022-07-29 Ｋｒａｓ変異体がんの処置のための方法および組成物

Country Status (7)

Country Link
US (1) US20240374597A1 (https=)
EP (1) EP4376959A4 (https=)
JP (1) JP2024527109A (https=)
KR (1) KR20240051145A (https=)
CN (1) CN118043075A (https=)
CA (1) CA3227802A1 (https=)
WO (1) WO2023010121A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121846289A (zh) * 2024-10-12 2026-04-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 包括nampt抑制剂和kras抑制剂的组合物及其用途
CN119607214B (zh) * 2025-02-17 2025-06-20 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
BR112021016149A2 (pt) * 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230028798A (ko) * 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
KR102379786B1 (ko) * 2020-08-13 2022-03-25 정부환 레일 형식 보행보조기구 방향전환장치

Also Published As

Publication number Publication date
CA3227802A1 (en) 2023-02-02
US20240374597A1 (en) 2024-11-14
EP4376959A4 (en) 2025-06-11
CN118043075A (zh) 2024-05-14
EP4376959A1 (en) 2024-06-05
WO2023010121A1 (en) 2023-02-02
KR20240051145A (ko) 2024-04-19

Similar Documents

Publication Publication Date Title
JP2024527109A (ja) Ｋｒａｓ変異体がんの処置のための方法および組成物
US11964015B2 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
US12383619B2 (en) Use of glutamate modulating agents with immunotherapies to treat cancer
JP2020525427A (ja) 癌を処置するための方法
JP2023538906A (ja) ネクチン－４に特異的な二環コンジュゲート及びその使用
CN115515577A (zh) 用于治疗癌症的atr抑制剂
US12295962B2 (en) Polymorphic compounds and uses thereof
JP2019510785A (ja) 癌を処置する方法
TW202327610A (zh) 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
TWI812820B (zh) 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
US20230193399A1 (en) Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma
WO2017205514A1 (en) Methods of sensitizing cancer to immunotherapy
US20220096436A1 (en) Combination product for the treatment of cancer
ES2763118T3 (es) Terapia contra el cáncer con parvovirus H-1 combinado con un anticuerpo anti-PD1 o anticuerpo anti Pd-L-1
US20220257777A1 (en) Hsp90-binding conjugates and combination therapies thereof
JP2024503513A (ja) がんを処置するための併用療法スケジュール
WO2022155311A1 (en) Methods and systems for analysis of drug target engagement and treatment of cancer
TW202602455A (zh) 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
CN119818513A (zh) 治疗儿科患者的癌症的方法
HK1261030A1 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
HK1261030B (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
NZ745264B2 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250728